National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

HuC242-DM4
An immunotoxin of a humanized monoclonal antibody C242 (MoAb HuC242) conjugated with a derivative of cytotoxic agent maytansine, DM4, with potential antitumor activity. huC242-DM4 is generated based on MoAb C242, which is raised against a cell surface superantigen, CA242, found in a variety of human tumor cells. Upon binding and entry, the immunoconjugate releases the maytansinoid agent DM4, which binds to tubulin, thereby affecting microtubule assembly/disassembly dynamics. As a result, this agent prevents cell division and reduces cell growth of cancer cells that express CA242. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:maytansinoid DM4-conjugated humanized monoclonal antibody huC242



Previous:HspE7, HSV-TK-transduced donor lymphocytes, hTERT I540/R572Y/D988Y multipeptide vaccine, hu14.18-IL2 fusion protein, huBC1-huIL12 fusion protein AS1409
Next:human anti-alpha-v integrin monoclonal antibody, human anti-TGF-beta monoclonal antibody GC1008, human gp100 plasmid DNA vaccine, human monoclonal antibody 216, human monoclonal antibody B11-hCG beta fusion protein CDX-1307

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov